Horowitz, MA;
Moncrieff, J;
(2020)
Are we repeating mistakes of the past? A review of the evidence for esketamine.
The British Journal of Psychiatry
pp. 1-4.
10.1192/bjp.2020.89.
(In press).
Preview |
Text
Moncrieff_Esketamine article BJPsych 2nd re-submission April 2020 'clean' copy.pdf - Accepted Version Download (217kB) | Preview |
Abstract
Esketamine has been licensed for 'treatment-resistant depression' in the USA, UK and Europe. Licensing trials did not establish efficacy: two trials were negative, one showed a statistically significant but clinically uncertain effect, and a flawed discontinuation trial was included, against Food and Drug Administration precedent. Safety signals - deaths, including suicides, and bladder damage - were minimised.
| Type: | Article |
|---|---|
| Title: | Are we repeating mistakes of the past? A review of the evidence for esketamine |
| Location: | England |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1192/bjp.2020.89 |
| Publisher version: | http://dx.doi.org/10.1192/bjp.2020.89 |
| Language: | English |
| Additional information: | This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions. |
| Keywords: | Esketamine, antidepressants, depression, ketamine, suicide |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > Division of Psychiatry |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10125093 |
Archive Staff Only
 |
View Item |
